Drug intelligence / Profile preview

busulfan + melphalan + thiotepa

Development stage
Phase 3
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Busulfan + melphalan + thiotepa is a combination chemotherapy regimen consisting of three alkylating agents—busulfan, melphalan, and thiotepa. This regimen is primarily used as a high-dose conditioning treatment before autologous or allogeneic stem cell transplantation in patients with aggressive hematologic malignancies such as non-Hodgkin's lymphoma, Hodgkin's disease, acute leukemias, and central nervous system lymphomas. The combination works by cross-linking DNA strands and inhibiting DNA replication and transcription, leading to cell death in rapidly dividing cancer cells. It is often chosen for patients who have previously received radiotherapy that precludes the use of total body irradiation-based regimens[2][3][4][6].

Other names
TBM regimenthiotepa + busulfan + melphalan
02

Targets

DNANeuraminidase

Beyond the preview

Go deeper on busulfan + melphalan + thiotepa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on busulfan + melphalan + thiotepa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call